Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation

A.A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Charlestown, MA 02129, USA.
European Journal of Neuroscience (Impact Factor: 3.67). 11/2009; 30(11):2143-50. DOI: 10.1111/j.1460-9568.2009.07015.x
Source: PubMed

ABSTRACT We investigated the effects of disease progression on brain regional neurochemistry in a mutant mouse model of familial amyotrophic lateral sclerosis (FALS; the G93A model) using in vivo and in vitro magnetic resonance spectroscopy (MRS). There were numerous changes in the brain spectra that were brain region dependent. At early time points starting around 80 days of age there were increases in brain glutamate. At later time points there were more extensive changes including decreased N-acetyl aspartate and glutamate and increased glutamine, taurine and myo-inositol. The effects of the disease were most severe in spinal cord followed by medulla and then sensorimotor cortex. There were no changes noted in cerebellum as a control region. The effects of creatine supplementation in the diet (2%) were measured in wild-type and FALS animals in medulla, cerebellum and cortex. The increase in brain creatine was largest in cerebellum (25%) followed by medulla (11%) and then cortex (4%), reflecting the ordering of creatine kinase activity. There was a protective effect of creatine on N-acetyl aspartate loss in the medulla at late stages. Creatine supplementation had a positive effect on weight retention, leading to a 13% increase in weight between 120 and 130 days. MRS shows promise in monitoring multiple facets of neuroprotective strategies in ALS and ALS models.

  • Source
    • "T2 weighted MRI also revealed early and progressive degeneration in the trigeminal, facial and hypoglossal brain stem (Evans et al., 2014) that was replicated in human SOD1 patients who showed cortical hyperexcitability prior to symptom onset (Vucic et al., 2008). Magnetic resonance spectroscopy (MRS) has been used to demonstrate decreases in N-acetylaspartate (NAA) in the motor cortex of SOD1 G93A associated with the degree of motor dysfunction (Choi et al., 2009). Electrophysiologic measures have gained ground as a way to monitor the muscle itself. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The past decade has seen a dramatic increase in the discovery of candidate biomarkers for ALS. These biomarkers typically can either differentiate ALS from control subjects or predict disease course (slow versus fast progression). At the same time, late-stage clinical trials for ALS have failed to generate improved drug treatments for ALS patients. Incorporation of biomarkers into the ALS drug development pipeline and the use of biologic and/or imaging biomarkers in early- and late-stage ALS clinical trials have been absent and only recently pursued in early-phase clinical trials. Further clinical research studies are needed to validate biomarkers for disease progression and develop biomarkers that can help determine that a drug has reached its target within the central nervous system. In this review we summarize recent progress in biomarkers across ALS model systems and patient population, and highlight continued research directions for biomarkers that stratify the patient population to enrich for patients that may best respond to a drug candidate, monitor disease progression and track drug responses in clinical trials. It is crucial that we further develop and validate ALS biomarkers and incorporate these biomarkers into the ALS drug development process.
    Brain Research 10/2014; 1607. DOI:10.1016/j.brainres.2014.10.031 · 2.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper introduces recent advances in research on 3D shape ontologies. The purpose of shape ontologies is to formalize the characteristics of 3D geometric primitives so as to bridge the gap between knowledge-level representation of shapes in the human mind and their low-level computer graphics representations. In the formalizations described in this paper, an intermediate symbolic representation in the form of implicit, parametric functions is used for this purpose. With this intermediate level representation of shape knowledge it becomes possible to interactively change the “meaning” of a primitive by transforming its parametric space according to information extracted from natural language and/or hand gestures. Furthermore, “meaningful” hierarchical combinations of shapes into complex shapes also becomes possible because they can also be parameterized and thus formalized
    Robot and Human Communication, 1995. RO-MAN'95 TOKYO, Proceedings., 4th IEEE International Workshop on; 08/1995
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cause of the fatal motor neuron disease, amyotrophic lateral sclerosis (ALS), remains largely unknown. Most cases of ALS are sporadic and, for ~20% of familial ALS patients, mutations in the superoxide dismutase-1 (SOD1) gene have been identified. Transgenic rodents overexpressing mutant SOD1 emulate the disease and constitute the best ALS animal model so far. Several lines of evidence suggest that ALS is a multifactorial condition. In this review, we discuss the question of the involvement of the glutamate pathways in ALS-induced motor neuron death. As such, we review the data implicating glutamate metabolism alterations, glutamatergic environmental toxins, glutamate transporter/receptor defects, and Ca2+-mediated glutamate toxicity in the etiopathogenesis of ALS. Given the published data, we contend that glutamate-induced neurotoxicity more likely precipitates motor neuron degeneration rather than being the initiating factor of ALS. Furthermore, we propose that glutamate-induced neurotoxicity participates in the ALS deadly molecular cascade only as an executioner to put an end to a series of molecular perturbations that have irreversibly compromised motor neuron function. This could provide an explanation for the modest effect of therapeutic strategies targeting the glutamatergic system, including the only currently FDA-approved ALS treatment, riluzole. As in diseased motor neurons, overwhelming Ca2+ overload may be the converging point for glutamate, endoplasmic reticulum stress, and mitochondrial dysfunctional pathways, and only therapies targeting these simultaneously or targeting the earliest alterations initiating this deleterious cascade may have a real impact on halting ALS progression.
    Journal of Receptor, Ligand and Channel Research 12/2010; 2011(4):1-22. DOI:10.2147/JRLCR.S6504
Show more


Available from